105467-17-2

Basic information

• Product Name: Boc-Arg(Tos)-Gly-OMe
• CAS NO: 105467-17-2
• Molecular Weight: 499.588
• Mol File: 105467-17-2.mol

Chemical Properties

• CAS DataBase Reference: Boc-Arg(Tos)-Gly-OMe(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-Arg(Tos)-Gly-OMe(105467-17-2)
• EPA Substance Registry System: Boc-Arg(Tos)-Gly-OMe(105467-17-2)

Safety Data

• Hazardous Substances Data: 105467-17-2(Hazardous Substances Data)

Upstream product

• 13836-37-8 Boc-Arg(Tos)-OH 
• 616-34-2 methoxycarbonylmethylamine 

Downstream Products

• 1364570-56-8 17β-[Boc-Arg(Tos)-Gly-Asp(OBzl)-Ser(Bzl)-amido]-11α-hydroxyandrost-1,4-diene-3-one 
• 1364570-66-0 17β-[Boc-Arg(Tos)-Gly-Asp(OBzl)-Phe-amido]-11α-hydroxyandrost-1,4-diene-3-one 
• 1364570-17-1 17β-(Arg-Gly-Asp-Phe-amido)-11-α-hydroxyandrost-1,4-diene-3-one 
• 105916-77-6 N^α-Boc-N^δ-tosyl-Arg-OBt 

Relevant articles and documents

Novel nano-materials, RGD-tetrapeptide-modified 17β-amino-11α- hydroxyandrost-1,4-diene-3-one: Synthesis, self-assembly based nano-images and in vivo anti-osteoporosis evaluation

To find novel nano-materials with anti-osteoporosis activity and without side effects three novel anti-osteoporosis active amphiphiles, 17β-(RGD-AA-amido)-11α-hydroxyandrost-1,4-diene-3-one (5a: AA = Ser, 5b: AA = Val, 5c: AA = Phe), were constructed by coupling the bone resorption inhibiting active RGD-peptides and anti-osteoporosis active 17β-amino- 11α-hydroxyandrost-1,4-diene-3-one. In the solid state 5a, 5b and 5c exist as dispersed globes of 300 nm-14 μm in diameter, dispersed eggs of 110 nm-19 μm in diameter and beads of 238 nm-22 μm in diameter, respectively. In ultrapure water 1.1 μM of 5a, 5b and 5c form nano-globes of 33-400 nm, 16-278 nm and 54-187 nm in diameter, respectively. At an oral dose of 110 nmol kg -15a-c effectively inhibited mice from developing osteoporosis. In contrast to estradiol, 5a-c did not induce mice to develop endometrial hyperplasia and thrombus.

Development of three-component conjugates: To get nano-globes with porous surfaces, high in vivo anti-osteoporosis activity and minimal side effects

Three novel three-component conjugates of a succinyl spacer, a pharmacophore of 17β-amino-11α-hydroxyl-androst-1,4-diene-3-one, and a targeting sequence of RGD-tetrapeptide (peptide Arg-Gly-Asp-AA) were designed, synthesized, and evaluated. This paper presents evidence that inserting a succinyl functional group into the pharmacophore and the targeting sequence improves the oral anti-osteoporosis activities in mouse glucocorticoid model of secondary osteoporosis, which were reflected by dry weight, ash weight, Ca 2+ and bone mineral content of the femur of examined mice. These novel conjugates have no side effects on estrogen, and form nano-globes with a porous surface. This paper emphasizes that the hydrogen bond between the carbonyl group of the succinyl group and the carboxylic group of the C-terminal amino acid residue of RGD-tetrapeptides is the key to forming pores on the surface of the nano-globes of these novel conjugates.